Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease

被引:59
作者
Ahmad, Rawaha [1 ,2 ,3 ]
Postnov, Andrey [1 ,2 ,4 ]
Bormans, Guy [5 ]
Versijpt, Jan [6 ]
Vandenbulcke, Mathieu [2 ,7 ]
Van Laere, Koen [1 ,2 ,3 ]
机构
[1] Katholieke Univ Leuven, Dept Imaging & Pathol Nucl Med & Mol Imaging, Leuven, Belgium
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Univ Hosp Leuven, Div Nucl Med, Herestr 49 E901, B-3000 Leuven, Belgium
[4] Natl Res Nucl Univ MEPhI, Moscow, Russia
[5] Katholieke Univ Leuven, Lab Radiopharm, Leuven, Belgium
[6] Univ Hosp Brussels, Dept Neurol, Brussels, Belgium
[7] Katholieke Univ Leuven, Dept Psychiat, Old Age Psychiat, Leuven, Belgium
关键词
Cannabinoid type 2 receptor; CB2R; Neuroinflammation; PET imaging; Alzheimer's disease; POSITRON-EMISSION-TOMOGRAPHY; CB2; RECEPTORS; ACTIVATED MICROGLIA; MOUSE MODEL; HUMAN BRAIN; PET TRACER; NEUROINFLAMMATION; IDENTIFICATION; DEMENTIA; BINDING;
D O I
10.1007/s00259-016-3457-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The cannabinoid type 2 receptor (CB2R) is expressed by immune cells such as monocytes and macrophages. In the brain, CB2R is primarily found on microglia. CB2R upregulation has been reported in animal models of Alzheimer's disease, with a preferential localization near amyloid beta (A beta) plaques, and in patients post mortem. We performed in vivo brain imaging and kinetic modelling of the CB2R tracer [C-11]NE40 in healthy controls (HC) and in patients with Alzheimer's disease (AD) to investigate whether higher CB2R availability regionally colocalized to A beta deposits is present in vivo. Dynamic 90-min [C-11]NE40 PET scans were performed in eight HC and nine AD patients with full kinetic modelling using arterial sampling and metabolite correction and partial volume correction. All AD patients received a static [C-11]PIB scan 40 min after injection. In four HC, a retest scan with [C-11]NE40 PET was performed within 9 weeks to investigate test-retest characteristics. [C-11]NE40 was metabolized quickly leading to 50 % of intact tracer 20 min after injection and 20 % at 90 min. A two-tissue kinetic model fitted most of the time-activity curves best; both binding potential (BPND) and distribution volume (V (T)) parameters could be used. Brain uptake was generally low with an average K (1) value of 0.07 ml/min/ml tissue. V (T) and BPND were in the range of 0.7 - 1.8 and 0.6 - 1.6, respectively. Test values in HC were about 30 % for V (T) and BPND. AD patients showed overall significantly lower CB2R binding. No relationship was found between regional or global amyloid load and CB2R availability. Kinetic modelling of [C-11]NE40 is possible with a two-tissue reversible model. In contrast to preclinical and post-mortem data, [C-11]NE40 PET shows lower CB2R availability in vivo in AD patients, with no relationship to A beta plaques. A possible explanation for these findings is that [C-11]NE40 binds to CB2R with lower affinity and/or selectivity than to CB1R.
引用
收藏
页码:2219 / 2227
页数:9
相关论文
共 39 条
[1]   In vivo type 1 cannabinoid receptor availability in Alzheimer's disease [J].
Ahmad, Rawaha ;
Goffin, Karolien ;
Van den Stock, Jan ;
De Winter, Francois-Laurent ;
Cleeren, Evy ;
Bormans, Guy ;
Tournoy, Jos ;
Persoons, Philippe ;
Van Laere, Koen ;
Vandenbulcke, Mathieu .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (02) :242-250
[2]   Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects [J].
Ahmad, Rawaha ;
Koole, Michel ;
Evens, Nele ;
Serdons, Kim ;
Verbruggen, Alfons ;
Bormans, Guy ;
Van Laere, Koen .
MOLECULAR IMAGING AND BIOLOGY, 2013, 15 (04) :384-390
[3]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[4]  
Benito C, 2003, J NEUROSCI, V23, P11136
[5]   [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor [J].
Burns, H. Donald ;
Van Laere, Koen ;
Sanabria-Bohorquez, Sandra ;
Hamill, Terence G. ;
Bormans, Guy ;
Eng, Wai-si ;
Gibson, Ray ;
Ryan, Christine ;
Connolly, Brett ;
Patel, Shil ;
Krause, Stephen ;
Vanko, Amy ;
Van Hecken, Anne ;
Dupont, Patrick ;
De Lepeleire, Inge ;
Rothenberg, Paul ;
Stoch, S. Aubrey ;
Cote, Josee ;
Hagmann, William K. ;
Jewell, James P. ;
Lin, Linus S. ;
Liu, Ping ;
Goulet, Mark T. ;
Gottesdiener, Keith ;
Wagner, John A. ;
de Hoon, Jan ;
Mortelmans, Luc ;
Fong, Tung M. ;
Hargreaves, Richard J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (23) :9800-9805
[6]   In-vivo measurement of activated microglia in dementia [J].
Cagnin, A ;
Brooks, DJ ;
Kennedy, AM ;
Gunn, RN ;
Myers, R ;
Turkheimer, FE ;
Jones, T ;
Banati, RB .
LANCET, 2001, 358 (9280) :461-467
[7]   Endocannabinoids in Neuroimmunology and Stress [J].
Carrier, E. J. ;
Patel, S. ;
Hillard, C. J. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (06) :657-665
[8]   Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [J].
Christensen, Robin ;
Kristensen, Pernelle Kruse ;
Bartels, Else Marie ;
Blidda, Henning ;
Astrup, Arne .
LANCET, 2007, 370 (9600) :1706-1713
[9]   SPECTRAL-ANALYSIS OF DYNAMIC PET STUDIES [J].
CUNNINGHAM, VJ ;
JONES, T .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (01) :15-23
[10]   Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].
Dubois, Bruno ;
Feldman, Howard H. ;
Jacova, Claudia ;
Dekosky, Steven T. ;
Barberger-Gateau, Pascale ;
Cummings, Jeffrey ;
Delocourte, Andre ;
Galasko, Douglas ;
Gauthier, Serge ;
Jicha, Gregory ;
Meguro, Kenichi ;
O'Brien, John ;
Pasquier, Florence ;
Robert, Philippe ;
Rossor, Martin ;
Solloway, Steven ;
Stern, Yaakov ;
Visser, Pieter J. ;
Scheltens, Philip .
LANCET NEUROLOGY, 2007, 6 (08) :734-746